Can the heat shock protein 90 inhibitor geldanamycin be designed to specifically inhibit HER-2 tyrosine kinase?

This publication has 20 references indexed in Scilit:

• Synthesis and evaluation of antiproliferative activity of a geldanamycin–Herceptin™ immunoconjugate
  Bioorganic & Medicinal Chemistry Letters, 2000
• The Hsp90 Chaperone Family
  Published by Springer Nature ,1999
• The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy
  The International Journal of Cell Cloning, 1998
• Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
  Journal of Clinical Oncology, 1998
• Therapeutic application of anti-growth factor receptor antibodies
  Current Opinion in Oncology, 1998
• Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
  Proceedings of the National Academy of Sciences, 1996
• Polyubiquitination and Proteasomal Degradation of the p185c-B-2 Receptor Protein-tyrosine Kinase Induced by Geldanamycin
  Journal of Biological Chemistry, 1996
• p185erbB2 Binds to GRP94 in Vivo
  Journal of Biological Chemistry, 1996
• Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives
  Journal of Medicinal Chemistry, 1995
• Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.
  Proceedings of the National Academy of Sciences, 1994